Neurosearch denies share manipulation charges
COPENHAGEN (Reuters) - Danish biopharma firm Neurosearch A/S said on Wednesday charges of share price manipulation had been filed against it, but it denied the allegations and said it was working with the authorities to clear up the matter.
Neurosearch said the charges were related to an announcement in February 2010 in which the management of the company reported top-line results from a Phase III study with its Huntington's disease drug candidate Huntexil and then two months later reassessed and corrected the data in a new announcement.
"On the present basis, Neurosearch is denying the charges and is collaborating fully with the authorities in order to resolve the matter," the company said in a statement.
(Reporting by John Acher)
- Tweet this
- Share this
- Digg this
- Iran prosecutor gives government 30 days to block social media
- Islamic State closes in on Syrian town, refugees flood into Turkey
- New smartphone app gives sight to the blind
- Study asks whether artificial sweeteners may drive diabetes
- Exclusive - Iran seeks give and take on militants, nuclear program
Streets in the capital of Sierra Leone were deserted on Friday as the West African state began a contested, three-day lockdown in a bid to halt the worst Ebola outbreak on record. Full Article | Slideshow